

Associate, Boston

Tax



T: 617.573.4853
F: 617.305.4853
leonard.greenberg@skadden.com

Education

LL.M., Boston University
School of Law, 2018

J.D., Boston University School of Law,
2018 (*summa cum laude*)

A.B., Tufts University, 2012
(*magna cum laude*)

Bar Admissions

Massachusetts

Leo Greenberg represents domestic and international clients in an array of U.S. federal income tax matters. Mr. Greenberg advises public and private companies across industries on the buy-side and sell-side tax aspects of mergers and acquisitions. He also counsels multinational companies in the biopharmaceutical, technology, automotive, entertainment, insurance, energy, food and shipping industries on complex post-acquisition integration and cross-border tax planning. Additionally, Mr. Greenberg represents business clients in the tax aspects of public and private debt and equity offerings, redemptions, restructurings, intellectual property licensing and collaboration transactions, and bankruptcies.

Representative matters include:

- Acrisure LLC in its \$3.4 billion capital raise from BDT Capital Partners;
- ArQule, Inc. in its \$2.7 billion acquisition by Merck & Co., Inc.;
- Array BioPharma Inc. in its \$11.4 billion acquisition by Pfizer Inc.;
- Aspen Technology, Inc. in its pending \$11 billion mixed consideration business combination with the software business of Emerson Electric Co.;
- Carbonite, Inc. in its acquisition by OpenText TM, a transaction that valued Carbonite at an enterprise value of \$1.42 billion;
- Goldfinch Partners and The Baupost Group in their pending \$910 million carve-out acquisition of Western Union Business Solutions from The Western Union Company;
- The McClatchy Company in its Chapter 11 bankruptcy and Section 363 asset sale;
- MorphoSys AG in its \$1.7 billion acquisition of Constellation Pharmaceuticals, Inc. and its related financing transactions with Royalty Pharma plc;
- New Fortress Energy Inc. in its combined \$5 billion stock and cash acquisition of Hygo Energy Transition Ltd. and Golar LNG Partners LP;
- Strongbridge Biopharma plc in its acquisition by Xeris Pharmaceuticals, Inc. for stock and contingent value rights;
- Veritas Capital in its \$3 billion take-private acquisition of Cubic Corporation;
- Vertex Pharmaceuticals Incorporated in its \$950 million acquisition of Semma Therapeutics, Inc.; and
- WeWork Inc. in its business combination with BowX Acquisition Corp., a special purpose acquisition company.

Mr. Greenberg also regularly advises nonprofit organizations *pro bono* regarding obtaining and maintaining tax-exempt status. Additionally, he is a co-author of the United States chapter of *The Inward Investment and International Taxation Review*.